Alveron Pharma

Alveron Pharma, established in March 2019, is developing a unique coagulation platform technology and owns the world’s first cyclodextrin-based anticoagulant reversal agent. Alveron Pharma's proprietary cyclodextrin-based compounds accelerate clotting through a unique mechanism without initiating it. Therefore, these compounds can be used as systemic anti-bleeding agents, and our leading project focuses on developing a truly universal anticoagulant reversal agent.